Ledgf peptides and their compositions for treatment of degenerative diseases // 2617964
FIELD: biotechnology.SUBSTANCE: invention relates to production of full-length fragments of the eye lens epithelial growth factor (LEDGF), and can be used in medicine. LEDGF fragment with SEQ ID NO: 2 is obtained, which is used in pharmaceutical compositions for treatment of diseases associated with protein aggregation.EFFECT: invention can effectively treat diseases associated with protein aggregation, in particular ocular diseases.15 cl, 31 dwg
Recombinant protein mio-hsp, method of its production, injection preparation for muscle mass increase in farm animals, birds and animals of canids, as well as method of using preparation // 2613420
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology and can be used for increasing muscle mass of farm animals, livestock and canines. Fused protein is obtained, consisting of myostatin, Gli-Ser spacer and glucan binding domain of alpha-glucan binding domain of Streptococcus mutans (Mio-HSP), that is used to produce injection preparation for subcutaneous or intramuscular injections in a dose of 50–200 mcg of said protein per one kg of animal body weight or poultry. For producing recombinant protein is grown cell strain E. coli M15 [rMio-HSP] - producer of recombinant protein myocardial HSP, which is obtained by transformation of cells of E. coli M15 plasmid rMio-HSP M15 containing a nucleotide sequence gene coding myocardial HSP, then bind protein myocardial HSP in paragraph 1 in the cell extracts strain E. coli M15 [rMio-HSP] with alpha-glucan binding sorbent by affine interaction incubation procedure, with further washing from unbound bacterial proteins and separating end product.EFFECT: invention allows to effectively induce synthesis of specific antibodies to myostatin, inhibit and, consequently, stimulate growth of muscular tissue.4 cl, 7 tbl, 6 ex

Genetic nucleotide sequences of artificially modified gdnf with deleted pro-region, product of which has improved properties neural inductor and stimulator of formation of neural processes, suitable for therapy of neural injuries, ischemic strokes and neurodegenerative diseases, expression vector, modified with gdnf // 2595377
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Disclosed is cDNA of natural GDNF gene artificially modified by removal of pro-region, which in mammalian cells or tissues in standard vectors produces active specific GDNF. Invention also relates to an expression vector containing said cDNA, as well as to active specific GDNF encoded by said cDNA. During translation in cells and tissues said GDNF stimulates neural differentiation of stem and progenitor cells with formation of neural processes.EFFECT: invention increases activity of GDNF as neural inductor and stimulator of formation of neural processes and can be used in therapy of neurodegenerative disorders, traumatic disorders of innervation as well as ischemic cerebral apoplexies of mammals, including humans.3 cl, 13 dwg, 5 ex

Neuregulin antagonists and use thereof in treating malignant growth // 2587619
FIELD: biotechnology.SUBSTANCE: invention relates to method of increasing period of time to recurrence, and can be used in medicine. Neuregulin antagonists are obtained, which are anti-NRG1 antibody siRNK or shRNK targeted NRG1, or immune-adhesine to NRG1 for administering the previously recieved anticancer therapy, in combination with therapeutic agent specified in paclitaxel, cisplatin or their combination for delay time to recurrence or prevent development of cancer cell resistance to therapeutic agent.EFFECT: invention allows to increase period of time to recurrence, which increases survival rate of patients.10 cl, 8 dwg, 1 tbl, 8 ex

ethod of purifying growth factor protein // 2571926
FIELD: chemistry.SUBSTANCE: invention relates to biotechnology and particularly to a method of purifying G-CSF (granulocyte-colony stimulating factor) in a purification sequence using chromatography. The method includes performing chromatography at least once using a multimodal resin with a negatively charged ligand in the form of 2-(benzoylamino)butanoic acid. G-CSF is bound with the multimodal resin at pH in the range of 4-6.2. The G-CSF is eluted at pH higher than 6.3 or with an elution agent in an elution buffer, where said elution agent includes an amino acid having a backbone chain and/or high ionic force in the elution buffer selected from a group consisting of arginine, lysine and/or histidine. Concentration of the elution agent is in the range of about 0.1 M to about 2.0 M.EFFECT: present invention enables to obtain purified G-CSF with high output.14 cl, 14 dwg, 10 tbl, 11 ex

Antibodies, containing therapeutic tpo/epo mimetic peptides // 2559526
FIELD: medicine.SUBSTANCE: claimed invention relates to field of biotechnology. Claimed are: therapeutic antibody and therapeutic antibody fragment for increasing production of platelets, including thrombopoetin (TPO) mimetic peptide, which contains sequence IEGPTLRQWLAARA, and inserted as addition to C-terminus of constant region of light chain and/or in position of less than 20 amino acids following C-terminus of hinge region of heavy chain. In addition, described are composition, containing antibody or its therapeutically active fragment, and method of increasing production of platelets in individual, including introduction of said composition, as well as nucleic acid, coding antibody polypeptide, containing TPO mimetic polypeptide.EFFECT: invention enables higher and faster production of platelets in comparison with knows structures of antibody, where mimetic peptide is inserted instead of one of CDR.13 cl, 4 dwg, 9 ex

Fused protein or peptide with increased half lifetime in vivo, which is maintained due to slow release in vivo, and method for increasing half lifetime in vivo using it // 2503688
FIELD: biotechnologies.SUBSTANCE: physiologically active protein or polypeptide are fused with version of alpha-1-antitrypsin, which has at least one mutated aminoacid residue. Mutations are performed in the following positions: asparagine residue instead of proline residue in position 357; or asparagine residue instead of proline residue in position 357 and threonine residue instead of serine in position 359; or asparagine residue instead of proline residue in position 357 and serine residue instead of cysteine in position 232; or asparagine residue instead of proline residue in position 357, threonine residue instead of serine in position 359 and serine residue instead of cysteine in position 232.EFFECT: invention allows increasing half lifetime of physiologically active protein or polypeptide in vivo by maintaining its stable circulation in blood.7 cl, 13 dwg, 7 ex

Optimised method of purifying recombinant protein of growth factor // 2491290
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology, namely to method of obtaining purified recombinant GDF-5-like protein. Method includes destruction of E.coli cells by homogeniser of high pressure at pressure of destruction from 800 to 900 bar. Inclusion bodies are separated from destructed cells E.coli by centrifugation. Separated inclusion bodies are processed with denaturate buffer, which contains carbamide and L- arginine, for solubilisation. Solubilised monomer of recombinant GDF-5-like protein is purified by centrifugation and chromatography.EFFECT: invention makes it possible to obtain purified recombinant GDF-5-like protein with high output.7 cl, 10 dwg, 2 tbl, 5 ex

ethod for signal path blocking activated by wnt8 factors in animal cells by means of noggin family proteins // 2473561
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to molecular biology, specifically proteins regulating cell differentiation by Wnt family protein inhibition and may be used in medicine for prevention and treatment of the diseases caused by disturbed Wnt signal path activity. e.g. colon cancer, melanoma, carcinoma.EFFECT: invention enables blocking a signal path activated by the Wnt8 family factor in the animal cells by the introduction of nogginI or noggin2 protein into tissue containing Wnt8 protein in the amount effective for Wnt8 activity inhibition.3 dwg, 4 ex

ethod of cleaning thrombin solution from infectious particles // 2468032
FIELD: chemistry.SUBSTANCE: invention relates to biochemistry. A method of cleaning thrombin solution from infectious particles is provided. Macromolecules are added to the starting thrombin solution. The obtained solution is then passed through a nanofilter to obtain a thrombin solution free from infectious particles. Said macromolecule is not a nonionic surfactant, is different from thrombin and can be selected from a polymer containing at least 3 monomers of sugar, amino acids, glycols, alcohols, lipids or phospholipids. A thrombin-containing solution obtained using said method is also provided.EFFECT: invention increases efficiency of removing infectious particles from thrombin solution; thrombin output reaches 93% using said method.20 cl, 2 dwg, 13 tbl

Peptide showing growth stimulating activity of hepatocyte growth factor (hgf) // 2426740
FIELD: medicine.SUBSTANCE: peptide is described by general formula I: X1-X2-X3-X4-X5 (I) where XI represents Q or V; X2 represents P; X3 represents G or (β-A); X4 represents R, or X4 represents K with X1-Q or with X1-V and X3-(p-A); X5 represents G, where G is glycine, (β-A) is β-alanine, P is proline, V is valine, Q is glutamine, K is lysine, R is arginine.EFFECT: invention presents extended range of effective therapeutic agents involved in liver regeneration.4 dwg, 1 tbl, 3 ex

Hgf beta-chain versions // 2403261
FIELD: chemistry; biochemistry.SUBSTANCE: present invention relates to molecular biology and can be used in designing agent and methods of modulating body functions associated with HGF/c-met signalling pathway. The invention discloses HGF/c-met polypeptide-antagonists which are mutant forms of HGF which contain a mutation in the N-terminal part of the β-chain and/or in its dimerisation part. The disclosed polypeptides have lower biological activity compared to wild type HGG and can be used in modulating activity of c-met, cell proliferation, cell migration and angiogenic cell activity.EFFECT: invention describes a method of obtaining HGF muteins using DNA recombinant technology and agents which are necessary for its existence.22 cl, 8 dwg, 1 ex

Recombinant vascular endothelial growth factor (vegf) secreting escherichia coli bl21 (pvegf-a165) cell strain // 2395568
FIELD: chemistry; biochemistry.SUBSTANCE: invention pertains to biotechnology. In particular, the invention relates to an Escherichia coli BL21 (pVEGF-A165) strain and can be used to produce a vascular endothelial growth factor - GST-VEGF-A165 protein. A novel Escherichia coli BL21 (pVEGF-A165) cell strain is obtained, which is transformed by the pGEX-VEGF-A165 plasmid. This strain produces a recombinant GST-VEGF-A165 protein.EFFECT: invention enables to obtain a Escherichia coli BL21 (pVEGF-A165) strain which is stably transformed by plasmid which codes VEGF, and which secrete this factor in extracellular space when cultured in vitro.3 dwg, 4 ex

ethod of blocking signal path activated by tgf-beta factor of vgi in animal cells // 2391352
FIELD: chemistry; biochemistry.SUBSTANCE: invention relates to molecular biology, specifically to proteins which regulate cell differentiation through inhibition of the TGF-beta cell superfamily. The invention is aimed at treating and preventing diseases related to human VgI orthologs. Noggin2 protein which contains VgI protein is injected into tissue in amount which is efficient for inhibiting VgI activity.EFFECT: invention enables to solve the task of blocking the signal path activated by the TGF-beta factor of VgI in aniamal cells.2 dwg, 4 ex

Noggin2-based activin activity blocking method // 2354662
FIELD: chemistry.SUBSTANCE: invention refers to biotechnology, specifically to Noggin2 proteins and can be used in medicine. The signalling cascade activin is blocked by introducing Noggin2 in an organism, tissue or cell in amount effective to inhibit or decrease activin activity.EFFECT: invention allows blocking effectively activity of protein activin.2 dwg, 8 ex

Active angiogenesis-preventing immunetherapy // 2329824
FIELD: medicine.SUBSTANCE: invention refers to medicine and concerns angiogenesis-preventing immunotherapy. Invention substance includes immunogenic compositions for treatment of disorders associated with angiogenesis intensification, containing oligonucleotides, coding polypeptides VEGFR2, introduced as a part of plasmid or viral vectors, as well as polypeptides VEGFR2, oligonucleotides, coding autologous VEGF with damaged function of receptor activation, polypeptides VEGF and their combinations. Immunogenic compositions can be used for treatment of malignant neoplasms and metastasises, at benign neoplasm and chronic inflammatory and autoimmune diseases. Advantage of invention lies in humoral and cellular immunity induction by means of specified compositions.EFFECT: development of effective method angiogenesis preventive immunotherapy.19 cl, 11 ex, 7 tbl

Releasing peptides of growth hormone // 2323941
FIELD: medicine; pharmacology.SUBSTANCE: releasing peptides of growth hormone are described with formula (I): R1-А1-А2-А3-А4-А5-R2, where:А1 designates Aib, Apc or Inp; А2 designates D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl) or D-Тrp; А3 designates D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-2Ser(Bzl) or D-Trp; А4 designates 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl); А5 designates Apc, Dab, Dap, Lys, Orn or deleted; R1 designates hydrogen; and R2 designates NH2; and their pharmaceutically acceptable salts.EFFECT: pharmaceutical compositions and the methods of their application are presented.25 cl, 1 tbl, 2 ex

Purified immunogenic protein, its fragments and derivatives // 2304585
FIELD: biotechnology, immunology.SUBSTANCE: invention reports about preparing and characterizing two forms of Nogo protein bound with the natural myelin with respect to the presence of immunogenic properties in their. These two forms correspond to natural products of alternative splicing, their fragments and derivatives, in particular, derivatives comprising deletions in amino acid residues, and chimeric protein also and comprising novel immunogenic polypeptides and their fragments. Invention can be used in medicine for diagnostic and curative aims.EFFECT: valuable medicinal properties of protein.18 cl, 79 dwg, 3 tbl, 8 ex

Recombinant placental growth factor and method for production thereof // 2295535
FIELD: biotechnology, gene engineering, pharmaceutical industry, medicine.SUBSTANCE: method for production of recombinant placental growth factor (PLGF) includes culturing of modified prokaryotic cells containing inducible expression system of PLGF to produce OD600 of 14-50, followed by expression inducing, extraction, purification and solubilizing of inclusion bodies; enriching of obtained mixture with dimer a multimer form of expressed protein by anion exchange chromatography and isolation of PLGF preferably in dimmer form by reversed-phase chromatography.EFFECT: method for PLGF production with high specific activity and high yield.27 cl, 5 dwg, 5 ex

Stem cell proliferation inhibitor and stimulant and usage thereof // 2292352
FIELD: medicine.SUBSTANCE: agents are used modulating stem cells proliferation when treating people and animals and accelerating recovery process after peripheral blood chemotherapy.EFFECT: enhanced effectiveness of treatment.79 cl, 28 dwg, 44 tbl

Antibody raised to hldf, method for it preparing (variants), peptide showing antigenic and nucleic acid-hydrolyzing property and method for diagnosis of human cell anaplastic state // 2276672
FIELD: biotechnology, peptides.SUBSTANCE: invention relates to a method for preparing antibodies raised to human leukocyte differentiation factor (HLDF) or to HLDF fragment (31-38) representing peptide of the following structure: Arg-Arg-Trp-His-Arg-Leu-Glu-Lys possessing with antigenic and nucleic acids-hydrolyzing properties, and for diagnostic aims also. Antibodies are prepared from rabbit plasma blood immunized with three injections of antigens wherein synthetic HLDF factor or conjugate is used as antigens. Diagnosis of anaplastic state of human cells is carried out by using solutions of antibodies to HLDF factor or HLDF fragment (31-38) in the concentration 0.0013 mg/ml as biological markers. Invention provides carrying out the differential diagnosis of tumors and normal organs and effective detecting initial stages in cell differentiation disturbances.EFFECT: improved preparing method of antibody, improved method for diagnosis.6 cl, 21 dwg, 1 tbl

Nucleotide and amino acid sequences of ovicell factors for ovary follicle growth change in vivo or in vitro // 2270862
FIELD: biotechnology, veterinary science.SUBSTANCE: invention proposes nucleic acid molecule GDF-9B of wild and mutated types, polypeptide encoding by these nucleic acids, vector, construction, ligand and methods for using such nucleic acids and polypeptides. Proposed group o invention provides carrying out the modulation of the ovary follicle growth via activity of homodimers of GDF-9B and heterodimers of GDF-9B/GDF-9 both in vivo and in vitro. Invention can be used in animal husbandry for aim of active and passive immunization against these polypeptides for the follicle growth change.EFFECT: valuable properties of factors.35 cl, 9 dwg, 4 tbl, 4 ex

Isolated keratinocyte growth factor (kgf) protein, recombinant dna molecule, vector, method for construction of host cell, method for protein production, and pharmaceutical composition // 2250213
FIELD: biotechnology, in particular epithelial cell growth factors useful in production of new keratinocyte growth factor (KGF).SUBSTANCE: KGF protein is obtained by cultivation of recombinant host cell, transformed with vector containing DNA which encodes amini acid sequence of KGF protein. Obtained KGF protein in pharmaceutical composition is used for forcing of epithelial cell proliferation. Method of present invention makes it possible to produce KGF protein with specific mitogenic activity of 3.4 x 104 U/mg of protein in relation to keratinocyte cells.EFFECT: new keratinocyte growth factor.52 cl, 14 dwg, 3 tbl

Hemopoietic protein (variants), dna sequence, method for preparing hemopoietic protein, method for selective expansion of hemopoietic cells, method for producing dendritic cells, method for stimulating for producing hemopoietic cells in patient, pharmaceutical composition, method for treatment // 2245887
FIELD: biotechnology, molecular biology, medicine, genetic engineering, pharmacy.SUBSTANCE: the hemopoietic protein comprises the amino acid sequence of the formula: R1-L1-R1, R2-L1-R1, R1-R2 or R2-R1 wherein R1 represents the modified ligand flt-3; R2 represents the modified human IL-3, the modified or unmodified colony-stimulating factor. Modification of R1 is carried out by addition of N-end with C-end directly or through linker (L2) that is able to join N-end with C-end to form new C- and N-ends. The modified human IL-3 is prepared by replacing amino acids at positions 17-123. The human G-CSF is modified by exchange of amino acids. The hemopoietic protein is prepared by culturing cells transformed with vector comprising DNA that encodes the hemopoietic protein. The hemopoietic protein stimulates producing hemopoietic cells and this protein is used as a component of pharmaceutical composition used in treatment of humans suffering with tumor, infectious or autoimmune disease. Invention provides preparing multifunctional hemopoietic proteins eliciting the enhanced activity with respect to stimulation of hemopoietic cells and eliciting the improved physical indices. Invention can be used for preparing chimeric multifunctional hemopoietic proteins.EFFECT: improved preparing and producing method, valuable medicinal properties of protein.22 cl, 19 dwg, 18 tbl, 117 ex

ethods and drugs to stimulate growth and differentiation of megakaryocytes // 2158603
The invention relates to the field of medicine and biotechnology, namely to new proteins, which factors in the growth and development of megakaryocytes (MGDFs; mostly labeled Mp1-ligands), the biological activity of which is to stimulate the growth of megakaryocytes and their differentiation or maturation, which ultimately leads to the formation of platelets

Therapeutic protein // 2155810
The invention relates to a new protein - human stem cell factor (FGC, SCP), DNA sequences coding for this protein, its use in therapy, in particular for in vitro fertilization, as well as to pharmaceutical compositions containing such protein

Inhibitor of proliferation of stem cells and its use // 2155066
The invention relates to medicine, namely to the use of inhibitors of proliferation of stem cells

Onlineby, method thereof and pharmaceutical composition containing onlineby // 2139087
The invention relates to medicine, namely to the field of preparative biochemistry, and for onlinebingo, method of its production and pharmaceutical compositions containing onlineby

A dna fragment encoding neurotropic factor of the brain (bdnf), a protein bdnf and method thereof // 2131926
The invention relates to biotechnology, genetic engineering